Bayer Sees China Approval In Two Years Of Extra Use For Stroke Drug
This article was originally published in PharmAsia News
Executive Summary
A Bayer AG executive said the firm expects Chinese approval within the next two years of an expanded indication for its anticlotting drug, Xarelto (rivaroxaban), to prevent strokes and not just treat them.